Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Sigrid Therapeuctis AB on share issues
Mandate

Vinge advises Sigrid Therapeuctis AB on share issues

November 27, 2017

Vinge has advised Sigrid Therapeuctis AB in connection with a combined directed issue and rights offering.

Sigrid Therapeutics is pioneering a user-friendly product made of precisely engineered particles with extraordinary absorptive capacity. The product works mechanically in the gut to improve glycemic control in a safe and effective way.

Vinge’s team primarily consisted of Kristoffer Franzkeit and Astrid Karlsson.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026